Safety and efficacy of glivec prior to allografting for CML and Ph-positive ALL: European experience

被引：0
|
作者：
Deininger, MWN
Schleuning, M
Olavarria, E
Fischer, T
Nagler, A
Sayer, H
Boque, C
Volin, L
Piotelli, G
Russel, N
Wandt, H
Schanz, U
Greinix, H
Sponk, L
Sponk
Verdonck, L
Lennard, A
Wimmer, M
Hegenbart, U
Lange, T
Niederwieser, D
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
183
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [31] EFFICACY OF ALPHA-INTERFERON TREATMENT IN AN UNUSUAL CASE OF PH-POSITIVE LEUKEMIA
    HAAS, OA
    MOR, W
    BARTRAM, C
    AMBROS, P
    GASTL, G
    GADNER, H
    BLUT, 1987, 55 (04): : 295 - 295
  • [32] Genomic analysis of two rare cases of pediatric Ph-positive T-ALL
    Sato-Otsubo, Aiko
    Osumi, Tomoo
    Yoshida, Masanori
    Iguchi, Akihiro
    Fukushima, Takashi
    Nakabayashi, Kazuhiko
    Ogawa, Seishi
    Hata, Kenichiro
    Kato, Motohiro
    PEDIATRIC BLOOD & CANCER, 2022, 69 (03)
  • [33] EFFICACY AND SAFETY OF DASATINIB IN CML/ALL PH1+ IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USE PROGRAM
    Gozzini, A.
    Bosi, A.
    Santini, V
    Stagno, F.
    Di Raimondo, F.
    Abruzzese, E.
    Breccia, M.
    Alimena, G.
    Gobbi, M.
    Martinelli, G.
    Sora, F.
    Sica, S.
    Luciano, L.
    Rotoli, B.
    Cambrin, Rege G.
    Saglio, G.
    Orlandi, E.
    Lazzarino, M.
    HAEMATOLOGICA, 2008, 93 : S37 - S37
  • [34] Is Initial Dasatinib-Blinatumomab Therapy for Ph-Positive ALL in Adults Cost Effective?
    Bitran, Jacob D.
    Nabrinsky, Edward
    Bufalino, Shams
    Knouse, Phillip
    Galvez, Angel G.
    BLOOD, 2021, 138
  • [35] Extra BCR/ABL fusion mosaicism in 18p in a CML Ph-positive patient with erythroblastic transformation
    Vargas, MT
    Fernández-Novoa, CF
    Rodríguez, A
    Figueredo, A
    Reyes, J
    CANCER GENETICS AND CYTOGENETICS, 2006, 165 (02) : 185 - 186
  • [36] Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era:: SCT or TKIs?
    Ruiz-Argulles, G. J.
    Tarin-Arzaga, L. C.
    Gonzalez-Carrillo, M. L.
    Gutierrez-Riveroll, K. I.
    Rangel-Malo, R.
    Gutierrez-Aguirre, C. H.
    Cantu-Rodriguez, O. G.
    Gomez-Almaguer, D.
    Giralt, S.
    BONE MARROW TRANSPLANTATION, 2008, 42 (01) : 23 - 28
  • [37] Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    G J Ruiz-Argüelles
    L C Tarin-Arzaga
    M L Gonzalez-Carrillo
    K I Gutierrez-Riveroll
    R Rangel-Malo
    C H Gutiérrez-Aguirre
    O G Cantú-Rodríguez
    D Gómez-Almaguer
    S Giralt
    Bone Marrow Transplantation, 2008, 42 : 23 - 28
  • [38] Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory (R/R) Ph-Positive Acute Lymphoid Leukemia (ALL) With Extramedullary Disease: Our Experience
    Dragoescu, Maria
    Ghiaur, Alexandra
    Coriu, Daniel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S248 - S248
  • [39] Clonal chromosomal abnormalities in Ph-negative cells and clonal evolution in Ph-positive cells during treatment with Imatinib in a CML patient
    van Zelderen-Bhola, S. L.
    Verdonk, M. J. A.
    Nijhuis, J. V.
    Barge, R. M. Y.
    CHROMOSOME RESEARCH, 2005, 13 : 154 - 154
  • [40] Secondary chromosomal aberrations in 255 childhood cases of Ph-positive acute lymphoblastic leukemia (ALL).
    Harbott, J
    Heerema, NA
    Baruchel, A
    Camitta, BM
    Chessells, JM
    Gaynon, PS
    Janka-Schaub, G
    Pui, CH
    Sallan, SE
    Schrappe, M
    Valsecchi, MG
    Aricò, M
    BLOOD, 2000, 96 (11) : 710A - 710A
12345